Campbell & CO Investment Adviser LLC Acquires 16,779 Shares of Hologic, Inc. $HOLX

Key Points

• Campbell & CO Investment Adviser LLC increased its holdings in Hologic, Inc. by 74.1%, acquiring an additional 16,779 shares to reach a total of 39,427 shares valued at approximately $2,435,000.
• Other institutional investors, including Dark Forest Capital Management and Voya Investment Management, have also increased their stakes in Hologic, which is now 94.73% owned by institutional investors and hedge funds.
• Hologic's latest quarterly earnings report showed an earnings per share (EPS) of $1.08, surpassing analysts' expectations, and the company has set guidance for FY 2025 EPS between $4.230 and $4.260.

Campbell & CO Investment Adviser LLC lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 74.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,427 shares of the medical equipment provider's stock after purchasing an additional 16,779 shares during the period. Campbell & CO Investment Adviser LLC's holdings in Hologic were worth $2,435,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in HOLX. Dark Forest Capital Management LP raised its stake in Hologic by 7.9% during the 4th quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after buying an additional 223 shares during the period. Voya Investment Management LLC raised its stake in Hologic by 9.9% during the 4th quarter. Voya Investment Management LLC now owns 138,891 shares of the medical equipment provider's stock worth $10,013,000 after buying an additional 12,488 shares during the period. Kovitz Investment Group Partners LLC acquired a new position in Hologic during the 4th quarter worth approximately $264,000. Nebula Research & Development LLC raised its stake in Hologic by 140.9% during the 4th quarter. Nebula Research & Development LLC now owns 16,129 shares of the medical equipment provider's stock worth $1,163,000 after buying an additional 9,434 shares during the period. Finally, Coldstream Capital Management Inc. raised its stake in Hologic by 10.0% during the 4th quarter. Coldstream Capital Management Inc. now owns 10,354 shares of the medical equipment provider's stock worth $746,000 after buying an additional 944 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of Hologic stock opened at $68.26 on Monday. The company has a market cap of $15.18 billion, a PE ratio of 28.32, a price-to-earnings-growth ratio of 2.48 and a beta of 0.49. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The business has a 50 day moving average price of $65.90 and a 200-day moving average price of $62.40. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company's quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on HOLX shares. Stephens dropped their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. UBS Group upped their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Evercore ISI increased their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Finally, Raymond James Financial reissued an "outperform" rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.